---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134319"
form_type: "8-K"
ticker: null
cik: "0001305253"
company_name: "Eiger BioPharmaceuticals, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:53:36.978203+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Eiger sells Zokinvy global rights to Sentynl for $45.2M net in bankruptcy sale

## Summary
- Closed sale of Zokinvy (lonafarnib) worldwide rights to Sentynl Therapeutics; net base price $45.2M after $0.9M credit.
- Bankruptcy Court approved sale on April 23; deal closed May 3, 2024.
- Sentynl assumes manufacture and commercialization of Zokinvy.
- Company cautions securityholders that trading is highly speculative; holders may face significant or complete loss.
- During Chapter 11, Eiger will file monthly financial reports with SEC instead of 10-K/10-Q.

## SEC filing metadata
- accession: 0001193125-24-134319
- form_type: 8-K
- cik: 0001305253
- company_name: Eiger BioPharmaceuticals, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1305253/000119312524134319/0001193125-24-134319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1305253/000119312524134319/d834255d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134319
- JSON: https://secwatch.observer/filing/0001193125-24-134319.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134319.txt

## Key facts
- M&A Transactions
  Eiger BioPharmaceuticals, Inc. completed a disposition involving Sentynl Therapeutics, Inc. for net base price in the amount of $45.2 million (closed 2024-05-03).
  - Action: disposition
  - Counterparty: Sentynl Therapeutics, Inc.
  - Consideration: net base price in the amount of $45.2 million
  - Closing: 2024-05-03
  source text: the auction of a base price in the amount of $46.1 million less a credit in the amount of $0.9 million for the termination fee resulting in a net base price in the amount of $45.2 million, subject to certain purchase price adjustments, including a reduction of $100,000 per diem if the sale closed after April 24, 2024. At a hearing held on April 23, 2024, the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312524134319/0001193125-24-134319-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.